Inside ANEMIA of CKD: Projecting the Future Burden of Anemia of Chronic Kidney Disease and Benefits of Proactive Management: A Microsimulation Model of the Chinese Population
Consistent with trends in CKD burden in China, the prevalence of anemia of CKD is projected to increase, leading to greater related healthcare costs. The introduction of healthcare interventions designed to screen for and treat anemia more effectively could therefore reduce its future burden and related costs.
Authors
- Claudia Cabrera (ORCID: https://orcid.org/0000-0003-2778-1604)
- Yiqing Wu (ORCID: https://orcid.org/0000-0002-8697-6586)
- Juan José García Sánchez (ORCID: https://orcid.org/0000-0001-6546-7769)
- Chalet Zhang
- Lise Retat (ORCID: https://orcid.org/0000-0002-6689-3599)
- Laura Webber (ORCID: https://orcid.org/0000-0002-8976-1919)
- Joshua Card-Gowers (ORCID: https://orcid.org/0000-0002-9928-8862)
- Yuzheng Zhang (ORCID: https://orcid.org/0000-0002-4054-6740)
- Susan Grandy
- Li Zuo (ORCID: https://orcid.org/0000-0002-3668-004X)
- Jianwei Xuan (ORCID: https://orcid.org/0000-0003-4800-4935)
- Alexander M. Martin (ORCID: https://orcid.org/0009-0001-4863-3961)
- Jiaqi Yao (ORCID: https://orcid.org/0000-0003-0013-9355)
- Naveen Rao
- Dunming Xiao
Institutions
- AstraZeneca (United Kingdom) (GB)
- Sun Yat-sen University (CN)
- Peking University (CN)
- Fudan University (CN)
- Peking University People's Hospital (CN)
- China National Health Development Research Center (CN)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1007/s12325-024-02863-4
- Citations
- 1
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.45
Funders
- AstraZeneca